Ozempic Users Flock To Protein Shake Now Named America's Unhealthiest Bottled Drink
Fairlife's Core Power protein shakes have been named the unhealthiest bottled beverage in America by food and nutrition magazine Eat This, Not That!, despite their popularity among fitness enthusiasts and Ozempic users. The shakes' muscle-boosting reputation is overshadowed by concerns over their nutritional content, sparking surprise and concern among consumers.
A news portal consulted dietitian Mary Sabat, MS, RDN, LD, who identified the seven unhealthiest food choices-ranking Core Power Protein Shakes as the worst among them for health impact.
They are a go-to for many after a workout or to boost their protein intake, but Sabat says these drinks are highly problematic.
"I put these first because they are so highly marketed as a great source of protein and a healthy food when in reality they are a disaster to your metabolic health," Sabat says. "Core Power Protein Shakes may seem like a convenient post-workout drink, but a closer look at the ingredients reveals several health concerns."
She explains, "They use non-organic, conventional dairy, which often comes from cows fed GMO corn and soy and may contain residues of hormones and antibiotics-unlike grass-fed dairy, which is higher in omega-3s and CLA and free from harmful residues. The addition of carrageenan, a thickening agent linked to gut inflammation and irritation, further detracts from its health profile."
Sabat also points out other harmful ingredients.
"Artificial sweeteners like sucralose and acesulfame potassium are also used, both of which have been associated with gut microbiome disruption and potential carcinogenic effects in animal studies," she says.
Sabat adds, "Lastly, the label includes 'natural flavours," a term that can encompass up to 100 different undisclosed chemical additives, many of which are far from natural. Together, these ingredients make Core Power far less healthy than its marketing implie"s.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
No one had answers: So 25-year-old Aditya went from 189 kg to 103 kg by building his own diet; check his story
Aditya Subramanian once weighed 189.6 kg. He faced health issues and emotional struggles. He decided to change his life. Bariatric surgery became a tool for him. He customized his diet and exercise. He lost weight over three years. He went from 189 kg to 103 kg. Aditya shares his story to inspire others. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads 'Surgery was a tool, not a shortcut.' So he took charge of his healing 'I didn't punish my body, I partnered with it.' 'Progress didn't come fast, it came real.' Tired of too many ads? Remove Ads At just 25, Aditya Subramanian's weight peaked at 189.6 kg. He faced serious health challenges, emotional isolation, and the lingering impact of the pandemic. But instead of giving in, he made a choice—not to shrink himself into a number, but to reclaim his future. 'I wasn't just heavy, I felt invisible, broken, and tired of pretending I was okay.'Life at 189.6 kilos was difficult beyond words. His bed collapsed twice. Machines helped him breathe. He was battling high blood pressure, fatty liver, and was on the verge of diabetes. His body was in distress, but his spirit was too drained to react. COVID didn't just disrupt the world—it disrupted his relationship with food, body, and found himself eating not from hunger, but from loneliness and anxiety. Even after trying Ozempic , the results didn't come—and neither did peace. Financial strain as a student abroad only added to the it was a silent moment that shifted everything.'What hurt the most? The silence in my parents' eyes when they saw me at graduation… That look stayed with me longer than any diet ever did.'It was in that silence that Aditya realised he needed change—not for anyone else, but for returning to India, Aditya chose to undergo bariatric surgery. It was a decision made not for instant transformation, but for survival and real journey began after the surgery. The standard post-op diet didn't fit his lifestyle, especially as he moved between India and Australia. Many prescribed foods weren't even accessible. The plan felt generic and disconnected from his real consulted doctors across countries, connected with people who had lived similar journeys, and started tailoring his diet based on what his body truly needed. Bit by bit, he created a sustainable rhythm that worked for the idea that weight loss must be punishing, Aditya focused on healing, not restriction. His approach centered around nourishment and gentle movement—like walks and stretches—that he could manage even on low-energy days.'And when I couldn't show up at 100%, I showed up at 20%. But I showed up.'The progress came steadily. His body began responding. Breathing machines were no longer needed, medications reduced, liver functions improved, and blood sugar levels wasn't an overnight transformation. Over three years, Aditya reduced his weight from 189 kg to 103 kg. But more than physical change, it was a mental and emotional rebuild. He learned to trust himself, to not fear food or failure. The journey had taught him patience, resilience, and self-compassion.'This isn't just my story, it's a mirror for many who feel unseen.'Today, Aditya is back in Australia. Life continues with its ups and downs—financial responsibilities, emotional maintenance, and plans for skin removal surgery. But he stands proud of the road he's walked—one that was honest, thoughtful, and rooted in message is especially powerful for people from India and the diaspora. He wants to break the silence around weight struggles, which are too often met with shame instead of support.'We don't talk about it enough. We shame people instead of supporting them.''So here I am. Sharing not to impress, but to connect.'If even one person feels less alone reading this, Aditya's story will have served its deepest purpose.[With TOI inputs]
News18
6 hours ago
- News18
Doctors Flag Dangerous Trend As Mounjaro, Wegovy Misuse Spikes Among Indians For Quick Weight Loss
Last Updated: Originally developed to treat type 2 diabetes and medical obesity, GLP-1 receptor agonists like tirzepatide and semaglutide are now being widely misused for cosmetic weight loss When a 45-year-old air hostess began suffering from frequent vomiting and extreme fatigue, the initial assumption was that her erratic work hours were to blame. But a deeper investigation at Fortis Hospital in Mumbai revealed the real reason—she had been self-injecting Tirzepatide, a powerful drug meant for diabetes and medically supervised weight loss, without follow-up or guidance from any doctor. She claimed that she had received a prescription during an overseas consultation for pre-diabetes and weight concerns, but she continued the medicine on her own upon returning to India. 'Although the medicine was prescribed to her by an overseas doctor, she was not in touch with them. She didn't realise her side effects were linked to the drug," said Dr Shobha Manish Itolikar, consultant, internal medicine, Fortis Hospital Mulund. Eventually, side effects, including gastrointestinal distress and functional impairment set in—symptoms she didn't realise were linked to the drug. 'These are just some of the perils of the ongoing over-the-counter usage of newer drugs without proper surveillance by a doctor." This is not an isolated case. In fact, this case is part of a rapidly growing concern among Indian physicians. Originally developed to treat type 2 diabetes and medical obesity, GLP-1 receptor agonists like tirzepatide (marketed as Eli Lilly's Mounjaro) and semaglutide (marketed as Novo Nordisk's Wegovy and Ozempic) are now being widely misused for cosmetic weight loss. The Danish drugmaker's Wegovy was launched in India in July, and the American drugmaker's Mounjaro was launched in March. Dr Mayank Madan, director of gastrointestinal, minimal access, and bariatric surgery at CK Birla Hospital, Gurugram, said he sees 40-50 new such cases every month. 'As a bariatric and gastrointestinal surgeon, I am increasingly seeing more and more patients self-medicate with medications like Wegovy or Mounjaro for rapid weight loss—most often without proper medical monitoring. While they can be wonderfully effective if prescribed and monitored properly, unmonitored utilisation may lead to life-changing gastrointestinal and metabolic issues." The side effects range from chronic vomiting, acid reflux, severe constipation or diarrhoea, to nutritional deficiencies, gallstones, and even rare cases of pancreatitis. Some patients report prolonged weakness and muscle loss due to unintentional undernourishment. Novo Nordisk's Ozempic, the breakthrough weight loss drug which was originally approved only for diabetes, has a known history of off-label misuse globally as a 'slimming shot". Social media platforms are rife with posts glamorising these injectables as quick fixes for weight loss, even among non-diabetic individuals. This phenomenon, doctors say, has now trickled into India, where access to the drugs—either through overseas prescriptions, online purchases, or informal channels—has become dangerously easy. Dr Mohit Sharma, senior consultant, internal medicine and endocrinologist at Amrita Hospital, Faridabad, told News18, many patients now arrive at clinics after trying weight-loss diabetes drugs on their own. 'We are seeing more and more people coming to us after trying weight-loss diabetes drugs like Mounjaro and Wegovy on their own, without a doctor's advice. Many of them come in complaining of severe nausea, vomiting, stomach cramps, and feeling extremely weak or dehydrated." He explained that these medicines are very powerful and meant to be started in small doses, gradually increased under medical supervision. But people who self-prescribe often start with the wrong dose or don't know how to handle side effects. 'One big danger is that these medicines are not safe for everyone. If someone has hidden thyroid problems, kidney issues, or gut sensitivities, they can have serious side effects," he said. 'Also, many people stop the medicine suddenly if they feel sick, which can mess up their metabolism and lead to quick weight regain or unstable blood sugar levels." Eli Lilly India Acknowledges Misuse Concerns, Urges Caution Pharmaceutical giant Eli Lilly, which markets Mounjaro, has acknowledged the misuse concerns and emphasised the importance of medical oversight. 'Patient safety is Lilly's top priority. Mounjaro (tirzepatide) is approved for weight management in adults with obesity – it is not for cosmetic weight loss and Lilly neither promotes nor endorses the off-label use of tirzepatide for any individual," said an Eli Lilly India spokesperson in response to queries from News18. 'Patients should only use tirzepatide when prescribed by a licensed healthcare professional and prescriptions should be fulfilled and supplied only by registered pharmacies and providers. Any tirzepatide offered without a prescription or for purchase on the black market is unlawful. These products are either fake or being 'resold' by an individual who obtained them through illicit means. Both practices put patients at risk." The company further noted that it is working with regulators, law enforcement agencies, and online platforms globally to address the proliferation of counterfeit and unregulated versions of tirzepatide. 'Lilly has taken steps to help address the risks posed by the proliferation of counterfeit, fake, and unsafe products across the world. We encourage patients to consult their doctor or other healthcare professional regarding any side effects they may be experiencing and to ensure that they are getting genuine Lilly medicine." Don't Self-Prescribe. Visit Doctors to Choose the Best For You Dr Tarun Mittal, vice-chairperson and robotic bariatric surgeon at New Delhi-based Sir Ganga Ram Hospital, told News18 that while the drug mimics gut hormones to control appetite and blood sugar levels, it is not a one-size-fits-all solution. 'Tirzepatide (Mounjaro) is a weekly injection, and it mimics gut hormones to control appetite and blood sugar. Some people have reduced around 15-20 per cent of their total body weight using this drug," he said. However, he added that the medicine may not be effective for patients with morbid obesity, particularly those with a BMI above 50, trying to lose 40–50 kg. 'It's great for managing type 2 diabetes, but weight often comes back if you stop using it," he explained. 'Prolonged use can cause gastrointestinal issues such as severe nausea, diarrhoea, vomiting, and constipation. It slows down the emptying of the stomach, increasing the chances of reflux. It can also lead to pancreatitis, gallstones, gastroparesis, and eye-related issues. Therefore, it's not a magic pill but a serious treatment that should be followed under the strict supervision of a weight loss or bariatric surgeon. Avoid self-medication." top videos View all According to Dr Mittal, almost 10–15 per cent of the patients seen in their OPD are already using Mounjaro or other GLP-1 analogues without medical advice. He emphasised that bariatric surgery remains a safe and effective option for those with significant obesity. 'Bariatric surgery is a one-time procedure which offers, on average, 60–80 per cent of excess weight loss. It is a safe procedure that can help reverse type 2 diabetes, PCOS, sleep apnea, and more," he said. About the Author Himani Chandna Himani Chandna, Associate Editor at CNN News18, specialises in healthcare and pharmaceuticals. With firsthand insights into India's COVID-19 battle, she brings a seasoned perspective. She is particularly More Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! view comments Location : New Delhi, India, India First Published: August 07, 2025, 14:58 IST News india Doctors Flag Dangerous Trend As Mounjaro, Wegovy Misuse Spikes Among Indians For Quick Weight Loss Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Economic Times
a day ago
- Economic Times
Wegovy maker Novo Nordisk to reduce costs after $95 billion stock loss
Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company's stock. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company's Danish drugmaker, which boomed to become Europe's most valuable firm worth some $650 billion last year on the back of sales of its blockbuster weight-loss drug, is facing a pivotal moment as it battles rising competition that is denting sales. The company repeated its full-year guidance, days after slashing its 2025 sales outlook and replacing CEO Lars Fruergaard Jorgensen with veteran insider Maziar Mike Doustdar. Its market cap has fallen since peak to some $212 billion."We are taking measures to sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth," outgoing CEO Jorgensen said in a statement. Doustdar will take the helm on Thursday, with the firm facing tough questions from investors about how it can stay competitive in the booming weight-loss drug market against U.S. rival Eli Lilly and a wave of compounded copycat has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. U.S. law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or reported second-quarter sales of 76.86 billion Danish crowns ($11.92 billion), up 18% from last year, below analysts initial confirmed a 2025 sales growth forecast of between 8% and 14%, which was cut in a profit warning last week from the previous 13%-21%. It was the second time this year that the company cut its sales earnings before interest and taxation (EBIT) stood at 33.45 billion crowns, up 29% from a year ago.
